CL Use To Be Limited To Emergencies – India Official
This article was originally published in PharmAsia News
If India uses a compulsory licensing policy for pharmaceuticals, it is likely to confine the procedure to emergency needs only. Recent CL applications, such as one filed by Natco Pharma to export cancer generics of Roche's Tarceva (erlotinib hydrochloride) and Pfizer's Sutent (sunitinib malate) to Nepal, are unlikely to be granted. A senior official of the patent-overseeing Department of Industrial Policy and Promotion said the agency favors CL only in cases of "an extraordinary problem" such as a widespread epidemic that needs an immediate solution. (Click here for more
You may also be interested in...
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.